claimgotdeniedAnalyze

Rinvoq (upadacitinib) prior authorization denied appeal

JAK inhibitor for RA, PsA, AD, UC, Crohn's, AS

To appeal a denied prior authorization for Rinvoq (upadacitinib), file a written appeal within 180 days. The appeal must cite the insurer's clinical policy, include a letter of medical necessity from the prescriber, and document each criterion the policy requires. The most common winning evidence is documented prior therapy history and a specialist letter.

Typical PA criteria

  • FDA-approved indication with ICD-10
  • Prior trial of TNF inhibitor unless contraindicated
  • Specialist prescriber
  • TB/HBV/VZV screening and boxed-warning risk assessment

Why your PA was denied

  • TNF inhibitor step therapy not completed
  • Boxed-warning risk factors not addressed (age ≥50, CV risk, malignancy)
  • Screening labs missing
  • Non-specialist prescriber

Evidence that overturns the denial

  • ✓Prior TNF-i trial dates, dose, response, discontinuation reason
  • ✓Documentation addressing JAK boxed-warning risk (age, smoking, CV, malignancy history)
  • ✓Baseline TB/HBV/lipid panel
  • ✓Specialist letter of medical necessity

FDA boxed warning restricts JAK inhibitors to patients with inadequate response or intolerance to ≥1 TNF-i; expect payers to enforce this step aggressively.

Draft a Rinvoq (upadacitinib) appeal letter

Free analysis identifies the cited policy and missing evidence. Then a finished letter that maps your chart to the criteria.

Draft my appeal letter

FAQ

Why was my Rinvoq (upadacitinib) prior authorization denied?+

The most common reasons are: TNF inhibitor step therapy not completed; Boxed-warning risk factors not addressed (age ≥50, CV risk, malignancy); Screening labs missing. Your denial letter names the specific criteria you did not meet.

How do I appeal a Rinvoq (upadacitinib) denial?+

File a written appeal within 180 days that cites the insurer's clinical policy, includes a letter of medical necessity from the prescriber, and documents the criteria the insurer requires.

What evidence overturns a Rinvoq (upadacitinib) denial?+

Prior TNF-i trial dates, dose, response, discontinuation reason; Documentation addressing JAK boxed-warning risk (age, smoking, CV, malignancy history); Baseline TB/HBV/lipid panel.

What if the plan excludes Rinvoq (upadacitinib) entirely?+

Plan exclusions are different from medical-necessity denials. Check the Summary Plan Description. If the drug is fully excluded, an appeal will not overturn it; you may need a formulary exception or manufacturer assistance program.

Other drugs

Keep reading

Not legal or medical advice. This page is a self-help resource. You make your own decisions. Strip personal identifiers (name, date of birth, address, member ID) from any document before uploading or sharing. The information here summarizes commonly-published payer policies and federal rules; confirm against your specific plan document and the current denial letter before acting.